This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate growth. Reducing testosterone levels may inhibit the proliferation of prostate tumor cells that need testosterone to grow. Enzalutamide is an androgen receptor signaling inhibitor. It inhibits the activity of prostate tumor cell receptors, which may reduce proliferation of prostate tumor cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Adding relugolix and enzalutamide to radiation therapy may be more effective at treating patients with very high risk prostate cancer than giving any of these treatments alone.

Start Date19 Nov 2024

Sponsor / Collaborator

Northwestern University

[+1]

NCT06361810 / Not yet recruitingPhase 1/2IIT

A Phase 1/2 Open-label Study of Pembrolizumab Combined With PNT-2002 Radioligand Therapy in Patients With Metastatic Renal Cell Carcinoma

This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.

Start Date01 Nov 2024

Sponsor / Collaborator

Lantheus Medical Imaging, Inc.

[+1]

NCT05568537 / Not yet recruitingPhase 4IIT

Monitoring Prostate Cancer Tumor Response to Radiation Therapy Using Advanced Functional Magnetic Resonance Imaging (MRI) and Pylarify (18F-DCFPyL) PSMA Positron Emission Tomography (PET)

This is a voluntary research study to find out how using technology including advanced magnetic resonance imaging (MRI) and prostate-specific membrane antigen - positron emission tomography (PSMA-PET) scan imaging, in addition to combined prostate treatment using radiation therapy, brachytherapy (internal radiation treatment using small radioactive seeds placed inside the body) and androgen deprivation therapy (drug therapy to suppress hormones) can help doctors see, track and predict tumor response to treatment for prostate cancer patients. Participation in this study will consist of radiation planning and simulation, magnetic resonance imaging (MRI) and positron emission tomography and computed tomography scan (PET/CT). One MRI and PSMA PET/CT scan will be done prior to the start of first external beam radiation therapy (EBRT) fraction. At mid-treatment prior to the second brachytherapy fraction, an MRI and PSMA PET/CT will be done. A third scan will be performed after 75% testosterone recovery or 12 months post androgen deprivation therapy (ADT) [whichever comes first].

Start Date01 Oct 2024

Sponsor / Collaborator-

100 Clinical Results associated with [18F]DCFPyL

100 Translational Medicine associated with [18F]DCFPyL

100 Patents (Medical) associated with [18F]DCFPyL

Literatures (Medical) associated with [18F]DCFPyL

01 Jun 2024·International Journal of Biological Macromolecules

Unlocking the potential of phenolated kraft lignin as a versatile feed additive

Article

Author: Wei, Hai-Lin ; Wang, Wen-Lei ; Yang, Xiao-Hui ; Zhang, Ping-Hu ; Jing, Fei ; Li, Long ; Zhou, Yong-Hong

Lignin, a renewable natural antioxidant and bacteriostat, holds promise as a versatile, cost-effective feed additive. However, traditional industrial lignin faces limitations, including low reactivity, poor uniformity, and unstable properties, necessitating chemical modification. Complex modification methods pose economic and toxicity challenges, so this study adopted a relatively simple alkali-catalyzed phenolization approach, using phenol, catechol, and pyrogallol to modify kraft lignin, and characterized the resulting products using various techniques. Subsequently, their antioxidant, antibacterial, adsorption properties for heavy metal ions and mycotoxins, growth-promoting properties, and antiviral abilities were assessed. The phenolation process led to lignin depolymerization and a notable increase in phenolic hydroxyl content, particularly in pyrogallol-phenolated lignin (Py-L), rising from 3.08 to 4.68 mmol/g. These modified lignins exhibited enhanced antioxidant activity, with over 99 % inhibition against E. coli and S. aureus, and remarkable adsorption capacities for heavy metal ions and mycotoxins. Importantly, Py-L improved the growth performance of mice and reduced influenza mortality. Furthermore, density functional theory calculations elucidated the mechanism behind the enhanced antioxidant properties. This study presents a promising avenue for developing versatile feed additives to address challenges related to animal feed antioxidant supplementation, bacterial control, and growth promotion.

01 May 2024·Anti-Cancer Agents in Medicinal Chemistry

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Review

Author: Vishakha, S ; Kurmi, Balak Das ; Patel, Preeti ; Navneesh, N ; Jain, Ankit ; Gupta, Ghanshyam Das ; Verma, Sant Kumar

Abstract:New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.

01 Jan 2024·Theranostics

PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?

Review

Author: Sallam, Mohamed ; Muyldermans, Serge ; Benešová-Schäfer, Martina ; Nguyen, Nam-Trung ; Sainsbury, Frank ; Kimizuka, Nobuo

In 1853, the perception of prostate cancer (PCa) as a rare ailment prevailed, was described by the eminent Londoner surgeon John Adams. Rapidly forward to 2018, the landscape dramatically altered. Currently, men face a one-in-nine lifetime risk of PCa, accentuated by improved diagnostic methods and an ageing population. With more than three million men in the United States alone grappling with this disease, the overall risk of succumbing to stands at one in 39. The intricate clinical and biological diversity of PCa poses serious challenges in terms of imaging, ongoing monitoring, and disease management. In the field of theranostics, diagnostic and therapeutic approaches that harmoniously merge targeted imaging with treatments are integrated. A pivotal player in this arena is radiotheranostics, employing radionuclides for both imaging and therapy, with prostate-specific membrane antigen (PSMA) at the forefront. Clinical milestones have been reached, including FDA- and/or EMA-approved PSMA-targeted radiodiagnostic agents, such as [¹⁸F]DCFPyL (PYLARIFY^®, Lantheus Holdings), [¹⁸F]rhPSMA-7.3 (POSLUMA^®, Blue Earth Diagnostics) and [⁶⁸Ga]Ga-PSMA-11 (Locametz^®, Novartis/ ILLUCCIX^®, Telix Pharmaceuticals), as well as PSMA-targeted radiotherapeutic agents, such as [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto^®, Novartis). Concurrently, ligand-drug and immune therapies designed to target PSMA are being advanced through rigorous preclinical research and clinical trials. This review delves into the annals of PSMA-targeted radiotheranostics, exploring its historical evolution as a signature molecule in PCa management. We scrutinise its clinical ramifications, acknowledge its limitations, and peer into the avenues that need further exploration. In the crucible of scientific inquiry, we aim to illuminate the path toward a future where the enigma of PCa is deciphered and where its menace is met with precise and effective countermeasures. In the following sections, we discuss the intriguing terrain of PCa radiotheranostics through the lens of PSMA, with the fervent hope of advancing our understanding and enhancing clinical practice.

News (Medical) associated with [18F]DCFPyL

17 Jun 2024

·www.globenewswire.com

Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the Netherlands PARIS, June 17, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that with first doses in Austria administered in May 2024, it is making strong progress in the European roll-out of PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “Today’s news that PYLCLARI® is now available to patients with prostate cancer in Austria is a testament to Curium's dedication to and ambition for the country and health care professionals in Austria. PYLCLARI® is currently available in six European countries – with more countries planned for first doses in 2024. We are extremely proud to be improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose prostate cancer.” In Austria, prostate cancer is one of the most common cancers among men with around 7,000 new cases diagnosed nationwide every year. PYLCLARI® is being produced in Austria by Curium at its Linz premises, with first doses administered at KABEG Klinikum Klagenfurt and a hospital in Linz. Authorization to produce PYLCLARI® at Curium’s Linz site was granted by Austria’s Österreichische Agentur für Gesundheit und Ernährungssicherheit in October 2023. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

Drug ApprovalRadiation Therapy

30 May 2024

·www.globenewswire.com

Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer

PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that earlier this month patients in France received the first doses of PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL) indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Today’s news follows earlier announcements by Curium of the first doses for Greece in November 2023, and for 2024 first doses for Italy in February, for the Netherlands in March, and for Germany in May. Benoit Woessmer, PET Europe CEO at Curium commented, “We are extremely pleased with today’s news that PYLCLARI® is now available to patients with prostate cancer in France. As we continue to redefine the experience of cancer through our trusted legacy in nuclear medicine, the growing availability of PYLCLARI® in Europe is improving the choice of diagnostic radiopharmaceuticals available to physicians to better diagnose and monitor prostate cancer – ultimately for the benefit of patients with prostate cancer.” In France, prostate cancer is one of the most common cancers among men with around 60,000 new cases diagnosed nationwide every year. PYLCLARI® is being produced in France at Curium’s facilities in Bordeaux, Lyon, Nancy, Marseille, Paris, and Tours. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

Drug ApprovalRadiation Therapy

06 May 2024

·www.globenewswire.com

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced that today in Munich and Nurnberg, Germany the first commercial doses of PYLCLARI® have been delivered. PYLCLARI® (INN: Piflufolastat (18F) also known as (18F)-DCFPyL), is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings: Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent Benoit Woessmer, PET Europe CEO at Curium commented, “We are pleased with the growing availability of PYLCLARI® to more nuclear medicine physicians and their patients across Europe. With today’s announcement, we are extremely proud to be improving the choice of diagnostic modalities available to our customers in Germany – ultimately for the benefit of patients with prostate cancer.” In Germany, prostate cancer is the most common cancer among men with around 63,400 new cases diagnosed nationwide every year. Today’s announcement is part of the continued roll-out of PYLCLARI® across the European Union, which is now available for patients with prostate cancer in Greece, Italy, and the Netherlands. For more information about PYLCLARI®: www.pylclari.com In the U.S., Lantheus received approval for PYLARIFY® (Piflufolastat (18F) Injection) from the Food and Drug Administration (FDA) in May 2021. It is the #1 utilized PSMA PET agent in the U.S. market. The European rights were licensed by Curium from Progenics, a Lantheus company, in 2018. About Curium Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com For more information:Ross Bethell, VP, Head of Global CommunicationsCuriumcommunications@curiumpharma.com

Drug Approval

100 Deals associated with [18F]DCFPyL

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V09	DB14805

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diagnostic agents	NO	Curium PET France	27 Nov 2023
Diagnostic agents	EU	Curium PET France	27 Nov 2023
Diagnostic agents	IS	Curium PET France	27 Nov 2023
Diagnostic agents	LI	Curium PET France	27 Nov 2023
PSMA-Positive Prostatic Cancer	NO	Curium PET France	27 Nov 2023
PSMA-Positive Prostatic Cancer	LI	Curium PET France	27 Nov 2023
PSMA-Positive Prostatic Cancer	EU	Curium PET France	27 Nov 2023
PSMA-Positive Prostatic Cancer	IS	Curium PET France	27 Nov 2023
Prostatic Cancer	US	Progenics Pharmaceuticals, Inc.	26 May 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
PSMA-Positive Prostatic Cancer	NDA/BLA	CH	Curium PET France	22 Feb 2024
Prostatic Cancer	NDA/BLA	EU	Curium PET France	27 Jun 2022
Recurrent Prostate Carcinoma	Phase 1	FR	Curium PET France	07 Jul 2020
Renal Cell Carcinoma	Phase 1	-	Progenics Pharmaceuticals, Inc.	-
Renal Cell Carcinoma	Phase 1	-	The Johns Hopkins University	-
Renal Cell Carcinoma	Phase 1	-	Sidney Kimmel Cancer Center	-
Recurrent Prostate Carcinoma	Discovery	FR	Curium PET France	07 Jul 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MP18-18 (AUA2024)	Phase 2	Prostatic Cancer 18F-DCFPyL PSMA PET \| mpMRI	100	18F-DCFPYL	taittoojps(kpykwopnka) = xfmquvxldh gzzcgxypwn (lhboiphxgf ) View more	Positive	01 May 2024
NCT04727736 (CTgov)	Phase 2	Recurrent Prostate Carcinoma	47	18F-DCFPyL	pzohetkatl(jbcthpbwna) = mmoxkosvmz lpajntkkyn (bjskblguds, qdqgyzwzdz - opfktqcmjb) View more	-	15 Feb 2024
PREP protocol (ASCO_GU2023)	Not Applicable	Prostatic Cancer Adjuvant	-	<sup>18</sup>F-DCFPyL PSMA-PET (Primary RT (pRT))	(wwimjcmgba) = hajqlzxeam ybsyadcsoy (zovejwagjn, 3.1 - 8.9) View more	-	21 Feb 2023
PREP protocol (ASCO_GU2023)	Not Applicable	Prostatic Cancer Adjuvant	-	<sup>18</sup>F-DCFPyL PSMA-PET (Salvage/Adjuvant RT (sRT))	(wwimjcmgba) = tuywnnapng ybsyadcsoy (zovejwagjn, 0.6 - 3.4) View more	-	21 Feb 2023
PSMA-PET Registry for Recurrent Prostate Cancer (PREP) (ASCO_GU2023)	Not Applicable	-	177	<sup>18</sup>F-DCFPyL PSMA PET/CT (Node positive)	(munlvvknvp) = rertdzzfzb pphoakdluw (cgummmonpy )	-	21 Feb 2023
	Not Applicable	-	177	<sup>18</sup>F-DCFPyL PSMA PET/CT (Persistently detectable PSA after initial radical prostatectomy)	(munlvvknvp) = caxmjishlt pphoakdluw (cgummmonpy )	-	21 Feb 2023
NCT02981368 (OSPREY, ASCO_GU2022) Manual	Phase 2/3	Prostatic Cancer	345	18F-DCFPyL (Cohort A)	kbslukzdjq(rubfhdowjh) = Cohort A: 0(GS ≤6), 0(GS 3+4), 2.4(GS 4+3), 2.5(GS 8), 1.8(GS 9-10); Cohort B: 1.3ng/mL(PSA 0 to < 0.2), 5.43ng/mL(PSA 0.2 to < 4), 11.3ng/mL(PSA 4 to < 20), 9.7ng/mL(PSA 20 to < 50), 9.4ng/mL(PSA ≥50) wwbfripzqv (jgpfhrlfjp ) View more	Positive	16 Feb 2022
NCT02981368 (OSPREY, ASCO_GU2022) Manual	Phase 2/3	Prostatic Cancer	345	18F-DCFPyL (Cohort B)		Positive	16 Feb 2022
NCT02981368 (OSPREY, ASCO_GU2021)	Phase 2/3	Prostatic Cancer	117	PSMA-targeted 18F-DCFPyL-PET/CT (<sup>18</sup>F-DCFPyL-PET/CT)	bxfmyvcnwx(dgaswpjipx) = szkdbqyrfu dtzmwryckt (uyuxcgjrnl ) View more	-	02 Mar 2021
UW17009 (ASCO_GU2021)	Not Applicable	Oligometastatic Prostate Carcinoma	26	<sup>18</sup>F-DCFPyL	(fzspkbptev) = efrbcqjcqq hiszivmofk (wuaariyfie, [90.5, 97.7]) View more	-	02 Mar 2021
NCT02687139 (CTgov)	Not Applicable	Renal Cell Carcinoma	34	PET/CT+18F-DCFPyL	zirvgczecd(skzzmufqvh) = yvugswsywh rqlrmnstmw (lisyueknci, deaxhcgrfu - ghcoebgaat) View more	-	29 Apr 2020
NCT02981368 (OSPREY, ASCO_GU2020)	Phase 2/3	Prostatic Cancer	252	<sup>18</sup>F-DCFPyL PET/CT	jnwbdalvcb(rjygnybfpe) = rqrupvxtbu tjlnijlgop (bngnvkwlly ) View more	-	19 Feb 2020
NCT02523924 (CTgov)	Not Applicable	Adenocarcinoma of prostate	50	18F-DCFPyL	abcziroqzo(vmhhkgtxaq) = xorelheokf chqrackzkb (nupomjmyou, wkfbinjycz - lbapetcgkq) View more	-	31 Jan 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis